Our Mission

CMC-Rx Consultancy was created with the mission to provide unparallelled technical and operational management and oversight of CMC activities for Virtual Biotech companies.

We work remotely with drug developers in the US, Canada and Europe.

Who We Are

CMC‑Rx Consultancy is led by Jo Van Betsbrugge, PhD, President and Principal Consultant. Jo holds advanced training in Macromolecular and Physical Organic Chemistry (MSc) and Synthetic Organic Chemistry (PhD), and brings more than 20 years of industry experience in drug development.

Before founding CMC‑Rx Consultancy, Jo served as President of BioQuadrant Inc., where he contributed to the development of the first intranasal dry‑powder treatment for hypoglycemia (BAQSIMI™, FDA approved in 2019). He is formally trained in the preparation of CMC sections for INDs and NDAs and has extensive hands‑on experience across the development and GMP manufacture of diverse chiral and achiral small molecules, peptides, and peptide mimetics.

Jo’s development portfolio spans a broad range of therapeutic modalities, including dual‑acting gluco‑regulated insulin secretagogues, peripheral insulin sensitizers, HIV protease inhibitors, platelet and thrombin inhibitors, bradykinin and thromboxane antagonists, high‑potency opioid peptides, acetylcholinesterase (AChE) reactivators, MTHFR inhibitors, and phosphodiesterase inhibitors.

Jo is a member of the American Chemical Society (ACS) and the American Association of Pharmaceutical Scientists (AAPS).

CMC-Rx Consultancy was founded in 2018 by Myriam Triest, PhD. She holds the position of Vice-President & Senior Consultant Regulatory CMC. Myriam is trained at the PhD level in Physical Chemistry, and brings with her over 20 years of Drug Development experience. Myriam previously held the positions of Director of Product Development at Locemia Solutions, VP Quality Assurance at BioQuadrant Pharmaceutical Intermediates Inc, and - most recently - Senior Director Technical Operations at a Appili Therapeutics.

Why Choose Us?